India pharma, healthcare: 78 deals worth $1.9 bn in Q1 2026
Synopsis
India's pharma and healthcare sector held its ground in Q1 2026 with 78 deals worth $1.9 billion, but the real story is where the money is going — PE and VC hit their highest deal volumes since Q2 2022, with AI diagnostics, digital care, and preventive health attracting the bulk of early-stage bets, even as M&A values softened 40% on the absence of blockbuster transactions.
Key Takeaways
India's pharma and healthcare sector recorded 78 deals worth $1.9 billion in Q1 2026 , per Grant Thornton Bharat .
M&A comprised 30 deals worth $915 million , with values down approximately 40% sequentially.
PE/VC activity reached 45 deals worth $456 million — highest volumes since Q2 2022 , up 22% sequentially.
Early-stage rounds (pre-seed to Series A) accounted for about 69% of PE/VC deal volumes; 95% of deals were below $50 million .
IPO activity was limited to one issuance raising $18 million ; QIP saw two issuances totalling $500 million .
India's pharma and healthcare sector recorded 78 deals worth $1.9 billion in Q1 2026, with deal volumes holding steady even as overall values moderated in the absence of large-ticket transactions, according to a report released on Wednesday, 29 April 2026. The findings, published by Grant Thornton Bharat, point to a more selective investment environment where mid-market and growth-stage assets are drawing sustained interest despite cautious capital deployment.
M&A Activity: Stable Volumes, Softer Values
Mergers and acquisitions accounted for 30 deals worth $915 million during the quarter, with volumes remaining broadly stable while values moderated approximately 40% sequentially. The report attributed the decline primarily to the absence of large-ticket transactions rather than any structural pullback in deal appetite.
Domestic transactions continued to dominate M&A volumes. Most deals were sized below $50 million, particularly across hospitals, pharma, and biotech segments — a pattern the report describes as sustained mid-market consolidation driven by regional hospital acquisitions and strategic pharma deals.
PE and VC: Highest Volumes Since Q2 2022
Private equity and venture capital activity comprised 45 deals worth $456 million, marking the segment's highest deal volumes since Q2 2022 and representing an approximately 22% sequential rise. Early-stage rounds dominated, with pre-seed to Series A transactions accounting for about 69% of PE/VC deal volumes; nearly 95% of deals were sized below $50 million.
Investment activity was particularly robust in health tech and wellness segments, including AI-led diagnostics, preventive healthcare, and digital care platforms. The report highlights this as evidence of continued investor interest in scalable, tech-enabled healthcare models.
What the Sector Leaders Said
Bhanu Prakash Kalmath S.J., Partner and Healthcare Industry Leader at Grant Thornton Bharat, said:
Point of View
Likely watching US tariff policy and domestic pricing pressures before committing. The PE/VC surge to its highest volumes since Q2 2022 is more interesting: it reflects genuine conviction in India's digital health stack, but the concentration of deals below $50 million and at pre-Series A stage means most bets are still speculative. The sector needs a few of these early-stage plays to scale into credible exits before institutional capital follows in size.
NationPress
1 May 2026
Frequently Asked Questions
How many pharma and healthcare deals were recorded in India in Q1 2026?
India's pharma and healthcare sector recorded 78 deals worth $1.9 billion in Q1 2026, according to a Grant Thornton Bharat report. Deal volumes held steady even as overall values moderated due to the absence of large-ticket transactions.
What drove the moderation in M&A deal values in Q1 2026?
M&A values fell approximately 40% sequentially, primarily because of the absence of large-ticket transactions rather than a structural decline in deal interest. Most M&A deals were sized below $50 million, concentrated in hospitals, pharma, and biotech segments.
Why did PE and VC activity hit a multi-year high in Q1 2026?
PE and VC activity reached its highest deal volumes since Q2 2022, rising approximately 22% sequentially to 45 deals worth $456 million. Investors showed strong interest in AI-led diagnostics, preventive healthcare, and digital care platforms, reflecting appetite for scalable, tech-enabled models.
Which healthcare segments attracted the most investor interest in Q1 2026?
Health tech and wellness segments — including AI-led diagnostics, preventive healthcare, and digital care platforms — attracted the most robust investment activity. Grant Thornton Bharat also noted growing investor focus on digital health, specialised care, and consumer health assets.
What was the state of IPO and QIP activity in India's healthcare sector in Q1 2026?
IPO activity was limited, with one issuance raising $18 million — a sharp decline. QIP activity picked up modestly, with two issuances totalling $500 million during the quarter.
